Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Clinical amyloid imaging in logopenic progressive aphasia.

Mendez MF, Sabodash V.

Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):94-6. doi: 10.1097/WAD.0b013e3182a683de.

2.

Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.

Lehmann M, Ghosh PM, Madison C, Laforce R Jr, Corbetta-Rastelli C, Weiner MW, Greicius MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.

Brain. 2013 Mar;136(Pt 3):844-58. doi: 10.1093/brain/aws327. Epub 2013 Jan 28.

3.

Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.

Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, O'Neil JP, Lal RA, Dronkers NF, Miller BL, Gorno-Tempini ML.

Ann Neurol. 2008 Oct;64(4):388-401. doi: 10.1002/ana.21451.

4.

Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging.

Leyton CE, Villemagne VL, Savage S, Pike KE, Ballard KJ, Piguet O, Burrell JR, Rowe CC, Hodges JR.

Brain. 2011 Oct;134(Pt 10):3030-43. doi: 10.1093/brain/awr216. Epub 2011 Sep 9.

PMID:
21908392
5.

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM.

Arch Neurol. 2011 Nov;68(11):1404-11. doi: 10.1001/archneurol.2011.150. Epub 2011 Jul 11.

PMID:
21747008
6.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Laforce R Jr, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014.

7.

Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.

Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.

Int J Geriatr Psychiatry. 2015 May;30(5):505-13. doi: 10.1002/gps.4173. Epub 2014 Jul 7.

PMID:
25043833
8.

Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls.

Newberg AB, Arnold SE, Wintering N, Rovner BW, Alavi A.

J Nucl Med. 2012 Jun;53(6):902-7. doi: 10.2967/jnumed.111.099606. Epub 2012 May 10.

9.

Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.

Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, Mathis CA, Klunk WE, Price J, DeKosky S, Wester HJ, Schwaiger M, Kurz A.

Neuroimage. 2008 Jan 15;39(2):619-33. Epub 2007 Sep 21.

PMID:
17962045
10.

Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.

Wu KY, Hsiao IT, Chen CS, Chen CH, Hsieh CJ, Wai YY, Chang CJ, Tseng HJ, Yen TC, Liu CY, Lin KJ.

Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):714-22.

PMID:
24233127
11.

A case of logopenic primary progressive aphasia with C9ORF72 expansion and cortical florbetapir binding.

Saint-Aubert L, Sagot C, Wallon D, Hannequin D, Payoux P, Nemmi F, Bezy C, Chauveau N, Campion D, Puel M, Chollet F, Pariente J.

J Alzheimers Dis. 2014;42(2):413-20. doi: 10.3233/JAD-140222.

PMID:
24898647
12.

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline.

Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA; 45-A17 Study Group..

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):4-15. doi: 10.1097/WAD.0b013e318279d02a.

PMID:
23203162
13.

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.

Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE.

J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6. doi: 10.1136/jnnp-2012-302548. Epub 2012 Jul 11.

14.

Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.

Cortes-Blanco A, Prieto-Yerro C, Martinez-Lazaro R, Zamora J, Jiménez-Huete A, Haberkamp M, Pohly J, Enzmann H, Zinserling J, Strassmann V, Broich K.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S395-9. doi: 10.1016/j.jalz.2013.09.007. Epub 2014 Jan 10.

PMID:
24418060
15.

Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes.

Matías-Guiu JA, Cabrera-Martín MN, Moreno-Ramos T, Valles-Salgado M, Fernandez-Matarrubia M, Carreras JL, Matías-Guiu J.

J Neurol. 2015 Jun;262(6):1463-72. doi: 10.1007/s00415-015-7738-z. Epub 2015 Apr 11.

PMID:
25860346
16.

Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.

Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, Krautkramer MJ, Kung HF, Skovronsky DM, Hefti F, Clark CM.

Alzheimer Dis Assoc Disord. 2012 Jan-Mar;26(1):8-16. doi: 10.1097/WAD.0b013e31821300bc.

17.

The Alzheimer structural connectome: changes in cortical network topology with increased amyloid plaque burden.

Prescott JW, Guidon A, Doraiswamy PM, Roy Choudhury K, Liu C, Petrella JR; Alzheimer’s Disease Neuroimaging Initiative..

Radiology. 2014 Oct;273(1):175-84. doi: 10.1148/radiol.14132593. Epub 2014 May 22. Erratum in: Radiology. 2016 Apr;279(1):328.

18.

Impact of ¹⁸F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making.

Zannas AS, Doraiswamy PM, Shpanskaya KS, Murphy KR, Petrella JR, Burke JR, Wong TZ.

Neurocase. 2014 Aug;20(4):466-73. doi: 10.1080/13554794.2013.791867. Epub 2013 May 14.

PMID:
23672654
19.

Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia.

Gefen T, Gasho K, Rademaker A, Lalehzari M, Weintraub S, Rogalski E, Wieneke C, Bigio E, Geula C, Mesulam MM.

Brain. 2012 May;135(Pt 5):1554-65. doi: 10.1093/brain/aws076. Epub 2012 Apr 19.

20.

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury.

Mitsis EM, Riggio S, Kostakoglu L, Dickstein DL, Machac J, Delman B, Goldstein M, Jennings D, D'Antonio E, Martin J, Naidich TP, Aloysi A, Fernandez C, Seibyl J, DeKosky ST, Elder GA, Marek K, Gordon W, Hof PR, Sano M, Gandy S.

Transl Psychiatry. 2014 Sep 16;4:e441. doi: 10.1038/tp.2014.91.

Supplemental Content

Support Center